MS Society of Canada Grant to Support AI in Predicting Disease Course multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference.
After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected than others, a new analysis suggests.
The findings may have important implications for understanding how Mavenclad works in MS patients, as well as understanding how vaccines still may be effective in people taking this immune-suppressing therapy.
Mavenclad is an approved treatment for active relapsing forms of MS in the U.S. Originally developed to treat certain cancers, Mavenclad is believed to work by reducing levels of immune cells that drive inflammation in MS. However, it’s not clear exactly how immune cell dynamics are affected by Mavenclad treatment, or how these dynamics are tied to changes in MS symptoms following treatment.
4.5 (2)
TG Therapeutics has expanded its contract with Samsung Biologics to manufacture ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS).
“Samsung is the global leader in biologics manufacturing and we are happy to have them as our partner as we look forward to the potential commercialization of ublituximab across both oncology and autoimmune indications,” Michael S. Weiss, executive chairman and CEO of TG Therapeutics, said in a press release.
Ublituximab is an antibody designed to prevent B-cells from triggering the inflammation that causes nerve cell damage in MS. It does so by targeting a protein called CD20 that’s found on the B-cell surface.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to updated data from the ongoing EVOLVE-MS-1 Phase 3 clinical trial.
Vumerity, developed by Alkermes in collaboration with Biogen, lowers inflammation associated with MS by reducing levels of reactive oxygen species often called free radicals within nerve cells. This is expected to slow disease progression by reducing nerve cell damage.
It is similar to Tecfidera (dimethyl fumarate), but is expected to cause fewer gastrointestinal (GI) side effects.